Document:

<PAGE>

                                                                   EXHIBIT 10.5

                        COLLABORATIVE RESEARCH AGREEMENT

     This Collaborative Research Agreement (the "Agreement") is made as of the
24th day of March, 1999 ("Effective Date"), by and between Telik, Inc., a
Delaware corporation having a place of business at 750 Gateway Boulevard, South
San Francisco, California 94080, U.S.A. ("Telik") and Sankyo Company, Ltd., a
Japanese corporation having a place of business at 5-1, Nihonbashi Honcho 3-
chome, Chuo-ku, Tokyo 103-8426, Japan ("Sankyo").  Telik and Sankyo shall be
referred to herein individually as a "Party" and collectively as the "Parties."

                               Recitals

     Whereas, Telik possesses a library of compounds ("Telik Library") and
proprietary technology which enables it to classify and search compounds
according to their protein-binding capabilities ("TRAP Technology");

     Whereas, Sankyo has certain biological targets ("Sankyo Targets") for which
it desires to find activity-modulating compounds; and

     Whereas, Sankyo wishes to evaluate the ability of the Telik Library and
TRAP Technology to identify compounds that affect Sankyo Targets and that may
lead to candidates for pharmaceutical development;

     Now, Therefore, in consideration of the foregoing premises and the
covenants set forth below, the parties hereby agree as follows:

1.   [ * ]  Fee.

     1.1  Payment of Fee.  Sankyo shall pay Telik a [*] [*] in [*] [*],
and [*].  Telik shall send invoices to Sankyo [*] to the [*].  The
installment payments shall be made in U.S. dollars by wire transfer to a bank
account to be specified by Telik.

     1.2  Taxes.  Sample Supply Fee payments shall be made without deduction
other than such amount (if any) Sankyo is required by law to deduct or withhold.
If the Sample Supply Fee is subject to such deductions or other withholdings, it
shall be increased by an amount which shall equal, as nearly as possible, the
amount required to be deducted or withheld.

2.   Screening Activity.

     2.1  Screening Term.  The term during which Sankyo may perform the
screening activities set forth in this Article 2 (the "Screening Term") shall
begin on the Effective Date and

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
    BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
    EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE sECURITIES ACT OF 1933, AS
    AMENDED.

                                       1
<PAGE>

expire [ * ] later, provided however, that if Sankyo elects to choose Substitute
Selected Targets as provided in Section 2.4(a)(i), the Screening Term shall be
extended as described therein.

     2.2  Target Selection. During the first [ * ] of the Screening Term,
Sankyo may notify Telik in writing of Sankyo Targets against which Sankyo wishes
to screen compounds provided by Telik ("Proposed Targets").  Sankyo's
notification must provide the molecular identity of the Proposed Targets and
such other information as Telik may reasonably request to permit Telik to
confirm that none of such Proposed Targets is identical to, overlapping or
otherwise in conflict with (i) targets included in, or subject to any then-
existing restriction resulting from, any research collaboration between Telik
and a third party or (ii) targets that Telik was already actively pursuing prior
to receipt of Sankyo's notice (collectively, "Reserved Targets").  Telik shall
notify Sankyo in writing whether or not each Proposed Target is a Reserved
Target.  If a Proposed Target is not a Reserved Target, then the Proposed Target
will be deemed a "Selected Target" upon dispatch of Telik's notification.  Telik
shall list all Proposed Targets in the Appendix to this Agreement and shall
update such Appendix, as necessary, to indicate whether a Proposed Target
becomes a Selected Target and to delete all Reserved Targets.  Sankyo may
designate no more than ten (10) Selected Targets.

     2.3  Active Molecule Criteria.  Prior to the initiation of compound
screening against each Selected Target, the Parties will agree on the screening
results required for a compound provided by Telik as set forth in Section 2.4 to
be classified as an "Active Molecule."

     2.4  Screening Activity and Data Collection.

          (a)  Within [ * ] of the later of (i) the date that a Proposed Target
is deemed a Selected Target or (ii) the Parties' agreement regarding the Active
Molecule criteria for that Selected Target, Telik shall, based upon its
knowledge of the Telik Library and using the TRAP Technology, select and provide
to Sankyo approximately [ * ] compounds ("Initial Compounds") from the Telik
Library that Telik believes, in its sole discretion, represent maximum chemical
compound diversity in the Telik Library.  Telik shall provide such Initial
Compounds in quantities of approximately [ * ] per Initial Compound, per
Selected Target.  Sankyo shall screen each Initial Compound for activity in
relation to the Selected Target and provide all data (including but not limited
to the concentration at which a compound elicits a response which is 50% of the
maximum response in the assay being applied (the "EC\50\") for each Initial
Compound) resulting therefrom ("Initial Results") to Telik within [ * ] of
Sankyo's receipt of the Initial Compounds.  Sankyo hereby covenants that it will
not use the Initial Compounds for any purpose other than that set forth in this
Section 2.4(a), it will cease using the Initial Compounds after completion of
testing as set forth in this Section 2.4(a), and it will store and return unused
Initial Compounds as set forth in Section 2.4(f).

               (i) If none of the Initial Compounds has an EC\50\ equal to or
less than [ * ] or the Initial Results otherwise contain insufficient useful
information for Telik to select Secondary Compounds pursuant to Section 2.4(b),
then Telik will provide Sankyo with another set of Initial Compounds (the
"Substitute Initial Compounds"), in quantities of approximately [ * ] per
Substitute Initial Compound, per Selected Target. The Substitute Initial
Compounds shall be treated by both Parties as if they were Initial Compounds;
provided, however, that if none of

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE sECURITIES ACT OF 1933, AS
AMENDED.

                                       2
<PAGE>

the Substitute Initial Compounds has an EC\50\ equal to or less than [ * ] or
the Initial Results from the Substitute Initial Compounds otherwise contain
insufficient useful information for Telik to select Secondary Compounds, then

                   (1) Telik shall not be obligated to provide any additional
Compounds to Sankyo with respect to the relevant Selected Target, and Telik's
obligations under Article 5 with respect to such Selected Target shall
terminate; and

                   (2) Sankyo may, at its election, not later than [ * ] after
Telik's receipt of the Initial Results for the Substitute Initial Compounds for
a particular Selected Target, choose a new target in substitution for such
Selected Target ("Substitute Selected Target"), not to exceed ten (10)
Substitute Selected Targets in the aggregate. The Substitute Selected Targets
shall be treated by both Parties as if they were Selected Targets. If Sankyo
exercises its right to choose a Substitute Selected Target, the Screening Term
shall be extended as necessary to complete the screening process for such
Substitute Selected Target within the schedule described in this Article 2, but
in no event shall the Screening Term be extended by more than [ * ].

          (b)  Within [ * ] after receipt of the Initial Results, Telik shall,
based upon the Initial Results and using the TRAP Technology or any other search
technology available to Telik, select and provide to Sankyo an appropriate
number of additional compounds ("Secondary Compounds") from the Telik Library
that Telik believes, in its sole discretion, will exhibit the greatest
likelihood of activity in relation to the Selected Target.  Sankyo shall screen
each Secondary Compound for selected activity in relation to the Selected Target
and provide all data (including but not limited to the EC\50\ for each Secondary
Compound) resulting therefrom ("Secondary Results") to Telik within [ * ] of
Sankyo's receipt of the Secondary Compounds.  Sankyo hereby covenants that it
will not use the Secondary Compounds for any purpose other than that set forth
in this Section 2.4(b), it will cease using the Secondary Compounds after
completion of testing as set forth in this Section 2.4(b), and it will store and
return unused Secondary Compounds as set forth in Section 2.4(f).

          (c)  Within [ * ] after receipt of the Secondary Results, Telik shall,
based upon the Secondary Results and using the TRAP Technology or any other
search technology available to Telik, select and provide to Sankyo [ * ]
additional compounds ("Tertiary Compounds") from the Telik Library that Telik
believes, in its sole discretion, will exhibit the greatest likelihood of
activity in relation to the Selected Target.  Sankyo shall screen each Tertiary
Compound for selected activity in relation to the Selected Target and provide
all data (including but not limited to the EC\50\ for each Tertiary Compound)
resulting therefrom ("Tertiary Results") to Telik within [ * ] of Sankyo's
receipt of the Tertiary Compounds.  Sankyo hereby covenants that it will not use
the Tertiary Compounds for any purpose other than that set forth in this Section
2.4(c), it will cease using the Tertiary Compounds after completion of testing
as set forth in this Section 2.4(c), and it will store and return unused
Tertiary Compounds as set forth in Section 2.4(f).

          (d)  If Sankyo and Telik jointly determine that further screening
activity is necessary, then based upon the Tertiary Results and using the TRAP
Technology or any other search technology available to Telik, Telik shall select
and provide to Sankyo [ * ] additional compounds ("Quaternary Compounds") from
the Telik Library that Telik believes, in its sole

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE sECURITIES ACT OF 1933, AS
AMENDED.

                                       3
<PAGE>

discretion, will exhibit the greatest likelihood of assay activity in relation
to the Selected Target. Sankyo will screen each Quaternary Compound for selected
activity in relation to the Selected Target and provide Telik all data
(including but not limited to the EC\50\ for each Quaternary Compound) resulting
therefrom ("Quaternary Results") to Telik within [ * ] of Sankyo's receipt of
the Quaternary Compounds. Sankyo hereby covenants that it will not use the
Quaternary Compounds for any purpose other than that set forth in this Section
2.4(d), it will cease using the Quaternary Compounds after completion of testing
as set forth in this Section 2.4(d), and it will store and return unused
Quaternary Compounds as set forth in Section 2.4(f).

          (e)  The total number of Initial Compounds, Secondary Compounds,
Tertiary Compounds and Quaternary Compounds provided by Telik pursuant to this
Section 2.4 (collectively, the "Provided Compounds") shall be in the range of
approximately [ * ] to approximately [ * ] Provided Compounds per Selected
Target.  Telik shall provide to Sankyo any information Telik may have in its
possession regarding appropriate usage and handling of the Provided Compounds
concurrent with the delivery to Sankyo of such Provided Compounds.

          (f)  Beginning with receipt by Sankyo and continuing through the
completion of testing under Section 2.4(a), 2.4(b), 2.4(c) or 2.4(d), Sankyo
shall store any unused Initial Compounds, Secondary Compounds, Tertiary
Compounds or Quaternary Compounds, as applicable, in a secure location. Within
[ * ] of the completion of screening against a Selected Target, Sankyo will
return to Telik all unused Provided Compounds for that Selected Target unless
specifically authorized by Telik, in writing, to do otherwise.

3.   Identification and Disclosure of Chemical Structures.

     3.1  Not later than [ * ] after sending the Tertiary Results or, if
applicable, the Quaternary Results to Telik, Sankyo shall provide Telik with a
written list of the Provided Compounds in which Sankyo has an interest.  Telik
shall determine which of these Provided Compounds qualify as Active Molecules
and shall provide to Sankyo the two dimensional representations of the chemical
structures of the Active Molecules on Sankyo's list (the "Disclosed Active
Molecules").  In addition, to provide Sankyo with additional information for
evaluating the potential of the Disclosed Active Molecules, Telik may also
provide the two dimensional representations of the chemical structures of
certain other Provided Compounds, selected by Telik in its sole discretion, that
did not qualify as Active Molecules.  Sankyo will use the structural information
provided by Telik solely to evaluate whether it wishes to exercise its option,
set forth in Section 4.1, for a license to develop and commercialize such
Disclosed Active Molecules.  Sankyo hereby covenants that it will not use the
structural information for any other purpose.  If Sankyo does not submit to
Telik a written list of the Provided Compounds in which Sankyo has an interest
within the time permitted under this Section 3.1, Telik's obligations under
Article 5 with respect to the relevant Selected Target shall terminate.

     3.2  The parties anticipate that Telik will be conducting research
collaborations with third parties during the Screening Term with respect to
targets other than Selected Targets.  Telik will not provide to Sankyo under
Section 2.4 compounds as to which a third party has exercised an option to
obtain or has obtained license rights, or which has otherwise been reserved by a
third party ("Reserved Compound").  Nonetheless, the parties acknowledge that
the compounds provided to Sankyo under this Agreement may include compounds
provided to third parties

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE sECURITIES ACT OF 1933, AS
AMENDED.

                                       4
<PAGE>

under research collaborations or similar arrangements with such third parties.
Accordingly, a third party may, while Sankyo is screening a particular compound,
designate that compound a Reserved Compound. In such event, Telik will promptly
inform Sankyo that such compound has become a Reserved Compound, and all of
Sankyo's rights regarding that Reserved Compound, including those rights set
forth in Articles 2, 3 and 4, shall terminate. In no event will Telik provide
Sankyo with the chemical structure of such Reserved Compound. In the event that
a third party terminates or otherwise waives its rights to a Reserved Compound
that Sankyo has screened and which qualifies as an Active Molecule, Telik will
notify Sankyo that such compound is no longer a Reserved Compound and Sankyo may
elect, in its discretion and by written notice to Telik, to receive the two
dimensional representation of its chemical structure from Telik. Such compound
shall thereafter be deemed a Disclosed Active Molecule subject to Section 3.1
and Article 4.

4.   Option for Development and Commercialization License.

     4.1  License Option.  Effective upon Telik's delivery to Sankyo of the
structures of all of the Disclosed Active Molecules for a particular Selected
Target (the "Option Effective Date"), Telik hereby grants to Sankyo an option to
acquire an exclusive, worldwide license to develop and commercialize any or all
Disclosed Active Molecules for such Selected Target (the "License Option").  The
term of such option shall commence on the Option Effective Date and expire [ * ]
thereafter (the "Option Term").

     4.2  Exercise of License Option.  Sankyo shall exercise the License Option
described in Section 4.1 by (i) providing written notice to Telik, prior to the
expiration of the Option Term, identifying each Disclosed Active Molecule to
which Sankyo desires to procure a license (a "Sankyo-Reserved Molecule") and
(ii) negotiating and entering into a mutually agreed license agreement (the
"License Agreement") as set forth in Section 4.4 within [ * ] of the Option
Effective Date.

     4.3  Consolidation of Licensing Negotiations.  To facilitate the execution
of a single License Agreement covering Sankyo-Reserved Molecules related to more
than one Selected Target, Telik may, in its sole discretion, agree to extend the
negotiation period for a Selected Target if Sankyo provides, during the
negotiation period for that Selected Target, timely written notification of its
desire to procure a license for Disclosed Active Molecules related to one or
more additional Selected Targets.  As a result of such an extension, the parties
will have until [ * ] after the Option Effective Date for the last Selected
Target as to which Sankyo has provided timely notification under Section 4.2 to
negotiate and execute a License Agreement covering all such Selected Targets.

     4.4  License Agreement.  If Sankyo exercises the License Option, Telik
intends to provide Sankyo with exclusive, worldwide rights to all know-how and
under all patents, patent applications and patent claims owned by Telik to the
extent necessary or useful to the development and commercialization of products
that, in the course of their discovery, development or production, utilize or
incorporate the relevant Licensed Active Molecule (as defined below) or a
derivative thereof.  To this end, in the License Agreement Telik shall grant to
Sankyo an exclusive, worldwide license (with the right to sublicense) to make,
have made, use, import, offer for sale and sell such products.  The License
Agreement shall contain such other

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE sECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE sECURITIES ACT OF 1933, AS
AMENDED.

                                       5
<PAGE>

terms as are consistent with terms then-applied to products of similar market
potential arising out of or developed in the biopharmaceutical industry,
provided however that (i) the royalty rate payable to Telik on net sales of
products to be developed and commercialized under such license shall not exceed
[ * ]; and (ii) except for any patents or patent applications assigned to Sankyo
under such a License Agreement, in the event that any inventions arise out of
the development and commercialization of products incorporating the relevant
Licensed Active Molecule or a derivative thereof, inventions made by either
party shall be owned by the party that made such inventions and inventions made
jointly by the parties shall be owned jointly by the parties. Upon the execution
of a License Agreement, any Sankyo-Reserved Molecule that is subject to the
License Agreement shall become a "Licensed Active Molecule." If Sankyo prefers
the assignment by Telik of certain patent application(s) or patent(s) in lieu of
an exclusive license for such applications or patents, Telik is willing to
consider such a request during the negotiation of the License Agreement.

5.   Exclusivity.

     5.1  [ * ].  Commencing [ * ], Telik shall not thereafter perform [ * ]
other than that [ * ] which is within the scope of this Agreement, until the
earlier of (i) [ * ], (ii) [ * ], (iii) [ * ] of the [ * ] a [ * ] as described
in Sections [ * ], (iv) [ * ]; or (v) [ * ].

     5.2  Sankyo-Reserved Molecules. Upon receipt of Sankyo's notice pursuant to
Section 4.2, Telik shall remove each Sankyo-Reserved Molecule identified in such
notice from the Telik Library, and shall not conduct or permit to be conducted,
or grant any third party the right to conduct, any research, development or
commercialization of such Sankyo-Reserved Molecules, provided that:

          (a) Telik's obligations under this Article 5 with respect to any
Sankyo-Reserved Molecule not then the subject of an executed License Agreement
shall terminate [ * ] after the Option Effective Date for the relevant Selected
Target (or, if Telik grants an extension pursuant to Section 4.3, [ * ] after
the Option Effective Date for the last Selected Target as to which Sankyo
provided timely notification under Section 4.2).  Telik shall thereafter be free
to conduct or grant any third party the right to conduct research, development
and commercialization activities with respect to such Sankyo-Reserved Molecules.

          (b) Telik's obligations under this Article 5 with respect to any
Selected Target for which no Sankyo-Reserved Molecule is then the subject of an
executed License Agreement shall terminate [ * ] after the Option Effective Date
for such Selected Target (or, if Telik grants an extension pursuant to Section
4.3, [ * ] after the Option Effective Date for the last Selected Target as to
which Sankyo provided timely notification under Section 4.2).  Telik shall
thereafter be free to conduct or grant any third party the right to conduct
research, development and commercialization activities with respect to such
Selected Target, and Sankyo shall be free to conduct or grant any third party
the right to conduct research, development and commercialization activities with
respect to such Selected Target.

6.   Ownership of Data and Intellectual Property.

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       6
<PAGE>

     6.1  Data Ownership.  Prior to the expiration of the License Option for all
Disclosed Active Molecules for a Selected Target, the Initial Results, Secondary
Results, Tertiary Results, and Quaternary Results, if applicable, (the "Combined
Screening Results") pertaining to those Disclosed Active Molecules shall be
jointly owned by the Parties.  Upon the execution of a License Agreement
pursuant to Article 4, Telik shall grant to Sankyo the exclusive right to use
Telik's interest in the Combined Screening Results pertaining to the relevant
Licensed Active Molecules in the manufacture, use and sale of products
incorporating or based upon such Licensed Active Molecules, including analogues,
derivatives, or formulations thereof, and in the manufacture, use and sale of
products incorporating compounds identified via analysis of structure-activity
information gathered from the Combined Screening Results.  Upon the later of (i)
the expiration of the License Option for a Disclosed Active Molecule or (ii) the
passing of [ * ] from the Option Effective Date for a Sankyo-Reserved Molecule
(or, if Telik grants an extension pursuant to Section 4.3, [ * ] after the
Option Effective Date for the last Selected Target as to which Sankyo provided
timely notification under Section 4.2) for which no License Agreement was
executed, the Combined Screening Results pertaining to the Disclosed Active
Molecule or Sankyo-Reserved Molecule shall be solely owned by Telik;  Telik
shall have the right to use such Combined Screening Results for any purpose, and
Sankyo shall not have any right to use such Combined Screening Results.

     6.2  Ownership of Telik Library, Provided Compounds and TRAP Technology.
All right, title and interest in and to the Telik Library, Provided Compounds,
TRAP Technology, and any know-how, patents, or patent applications controlled by
Telik and pertaining to the above items shall remain exclusively with Telik,
subject only to the rights granted to Sankyo under Sections 2.4, 4.1, 4.4 and
5.2.  Sankyo agrees not to obtain or attempt to obtain patents on the Telik
Library, Provided Compounds, TRAP Technology, or use thereof without the express
written consent of Telik.

     6.3  Inventions. Notwithstanding the ownership of data set forth in Section
6.1, any inventions or discoveries (whether patentable or not) pertaining to,
and all information resulting directly from the activities of either party
pursuant to Articles 2 and 3 (the "Inventions"), will be solely owned by Telik.
Sankyo shall promptly disclose to Telik any Invention resulting from the
activities of Sankyo, its employees, agents or affiliates.  Sankyo agrees not to
obtain or attempt to obtain patents on the Inventions without the express
written consent of Telik.

          (a) Prior to the execution of a License Agreement pursuant to Article
4, Telik shall have the sole right to file, prosecute, maintain, enforce and
defend all patent applications and patents for Inventions and shall pay all
costs and fees incurred with respect to such activities.  Sankyo shall provide
Telik, at Telik's expense, any assistance reasonably requested by Telik for the
filing, prosecution, maintenance, enforcement or defense of such patents or
patent applications.  If Telik decides not to file a patent application for an
Invention and Sankyo so requests in writing, Telik shall file and prosecute such
a patent application and maintain any patent arising therefrom for so long as
Sankyo promptly pays all costs and fees incurred with respect to such activities
(including any costs associated with assistance provided by Sankyo at Telik's
request).  Telik shall not be obligated to file, prosecute or maintain any
patent application or patent for an Invention other than that for which Sankyo
has complied with the requirements set forth in the preceding sentence.  In no
event shall Telik be obligated to enforce or defend such

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       7
<PAGE>

patent application or patent for Inventions. Within [ * ] after the filing of a
patent application for an Invention, Telik shall provide Sankyo with written
notification that such filing has been made.

          (b)  Upon the execution of a License Agreement pursuant to Article 4,
Sankyo shall reimburse Telik for all patent filing, prosecution and maintenance
costs (including attorneys' fees) incurred by Telik as of the effective date of
such License Agreement regarding any patent or patent application for Inventions
licensed to Sankyo thereunder.  Thereafter, Sankyo shall promptly pay all patent
filing, prosecution and maintenance expenses for any patent or patent
application for Inventions licensed to Sankyo under the License Agreement.

7.   Representations and Warranties.

     7.1  Each Party represents and warrants to the other that:

          (a)  It will exercise due care in performing its obligations under the
Agreement.

          (b)  All documentation and other information conveyed by one Party to
another hereunder or in connection herewith, was, at the time it was conveyed or
provided, accurate and complete in light of the purposes for which it was
intended.

     7.2  THE PROVIDED COMPOUNDS ARE BEING SUPPLIED TO SANKYO ON AN "AS IS"
BASIS WITH NO WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY
OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT THEY ARE FREE
FROM THE RIGHTFUL CLAIM OF ANY THIRD PARTY, BY WAY OF INFRINGEMENT OR THE LIKE.
TELIK MAKES NO REPRESENTATIONS THAT USE OF THE PROVIDED COMPOUNDS WILL NOT
INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTIES.

8.   Acknowledgments and Covenants by Sankyo.

     8.1  Sankyo acknowledges and agrees that the Provided Compounds may have
biological and/or chemical properties that are unpredictable and unknown at the
time of transfer.  Sankyo hereby covenants that it will use the Provided
Compounds with caution and prudence and it will not use the Provided Compounds
for testing in or treatment of humans or in any other test not part of the
Appendix.

     8.2  Sankyo covenants that it will maintain reasonable security measures,
no less strict than it maintains to protect its own valuable tangible property,
against loss, theft or destruction of the Provided Compounds.

     8.3  Sankyo covenants that it shall not attempt to reverse engineer or
ascertain, by any means, the chemical structure or any other information
concerning any Provided Compound unless and until Telik has provided the
chemical structure to Sankyo.

9.   Confidentiality.

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES aCT OF 1933, AS
AMENDED.

                                       8
<PAGE>

     9.1  Definition of Confidential Information.  "Confidential Information"
shall mean any and all knowledge, know-how, Proposed Targets, Selected Targets,
Combined Screening Results, structures of Provided Compounds, practices,
processes, or other information received by one Party from the other Party
pursuant to this Agreement.

     9.2  Nondisclosure of Confidential Information.  Except to the extent
expressly authorized by this Agreement or otherwise agreed in writing by the
Parties, the Parties agree that, for the term of this Agreement and for [ * ]
after its expiration or termination, the receiving Party shall keep confidential
and shall not publish or otherwise disclose and shall not use for any purpose
other than as provided for in this Agreement any Confidential Information,
hereinafter defined, furnished to it by the other Party pursuant to this
Agreement unless the receiving Party can demonstrate by competent written proof
that such Confidential Information:

          (a)  was already known to the receiving Party, other than under an
obligation of confidentiality, at the time of disclosure by the other Party;

          (b)  was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the receiving Party;

          (c)  became generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act or omission of
the receiving Party in breach of such Agreements;

          (d)  was disclosed to the receiving Party, other than under an
obligation of confidentiality to a third party, by a third party who had no
obligation to the disclosing Party not to disclose such information to others;
or

          (e)  was independently discovered or developed by the receiving Party
without the use of Confidential Information belonging to the disclosing Party.

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       9
<PAGE>

     9.3  Authorized Disclosure.  Each Party may disclose Confidential
Information belonging to the other Party to the extent such disclosure is
reasonably necessary in the following instances:

          (a)  Filing or prosecuting patents relating to Inventions or licensed
products;

          (b)  Regulatory filings;

          (c)  Prosecuting or defending litigation;

          (d)  Complying with applicable governmental regulations;

          (e)  Disclosure to Affiliates, sublicensees, employees, consultants,
or agents, each of whom prior to disclosure must be bound by similar obligations
of confidentiality and non-use at least equivalent in scope to those set forth
in this Article 9;

          (f)  Disclosure to investment bankers, investors, and potential
investors of information relevant to their assessment of the disclosing company,
such as the existence of the Agreement, the general nature of the diseases for
which targets have been selected, the number (but not the identity) of targets
selected and the status of the project on a per target basis (without
identifying the target); and

          (g)  Disclosure by Telik, more than [ * ] after the expiration of a
deadline applicable to Sankyo as set forth in Sections 4.1, 4.2 or 4.3 without
appropriate action or response by Sankyo, of the Combined Screening Results
against the relevant, identified Selected Target for a Disclosed Active
Molecule, to third parties interested in pursuing such Selected Target or
Disclosed Active Molecule, provided however, that Telik will not disclose to
such third party that Sankyo selected such Selected Target.

In any event, the Parties agree to take all reasonable action to avoid
disclosure of Confidential Information except as permitted hereunder.

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE sECURITIES ACT OF 1933, AS
AMENDED.

                                       10
<PAGE>

     9.4  Publicity.  Any publication, news release or other public announcement
relating to this Agreement or to the performance hereunder, shall be first
reviewed and approved by both Parties, which approval shall not be unreasonably
withheld.

10.  Term; Termination.

     10.1 Term.  This Agreement shall become effective as of the Effective Date
and unless earlier terminated as provided in this Article 10, shall expire on
the later of (i) the expiration of the time to enter all License Agreements
under Section 4.2, or (ii) thirty-six (36) months after the Effective Date.

     10.2 Termination for Default.  In the event that either party to this
Agreement shall be in default of any of its material obligations hereunder and
shall fail to remedy such default within [ * ] after receipt of written notice
thereof, the party not in default shall have the option of terminating this
Agreement by giving written notice thereof, notwithstanding anything to the
contrary contained in this Agreement.

     10.3 Effect of Termination.

          (a)  In General.  Termination of this Agreement shall not relieve the
Parties of any obligations accruing prior to such termination.  In the event of
termination by Telik pursuant to Section 10.2 as a result of Sankyo's default of
a material obligation, Sankyo shall pay Telik any Sample Supply Fee accrued at
the time of termination but not yet paid.  Except to the extent necessary to
allow the Parties to exploit their respective rights pursuant to Section 6,
promptly after termination of this Agreement each Party shall return or dispose
of any know-how of the other in accordance with the instructions of the other,
including without limitation any compounds, assays or other biological or
chemical materials.

          (b)  Default by Telik.  Following Sankyo's termination of this
Agreement pursuant to Section 10.2 as a result of Telik's default of a material
obligation, [ * ].  If, as of the date of termination, Sankyo has not made
payments to Telik equal to or greater than [ * ], Sankyo shall make such
additional payment to Telik within [ * ] of the effective date of termination.
If, as of the date of termination, Sankyo's payments total an amount greater
than [ * ], Telik shall refund to Sankyo any excess amounts within [ * ] of the
effective date of termination.  Telik shall (i) disclose to Sankyo the
structures for the Provided Compounds that have been tested by Sankyo and
qualify as Active Molecules as of the date of Sankyo's termination and (ii)
grant to Sankyo a nonexclusive, royalty-free, perpetual worldwide license (with
the right to sublicense) to develop and commercialize products that, in the
course of their discovery, development or production, utilize or incorporate
such Disclosed Active Molecules.

     10.4 Surviving Obligations. The terms of Articles 6 and 9 and Section 12.9
of this Agreement shall survive expiration or termination of this Agreement.

11.  Governing Law; Dispute Resolution.

     11.1 Governing Law.  This Agreement shall be governed by and construed in
accordance with the domestic laws of the State of California, (i) without giving
effect to any choice or conflict of law provision or rule that would cause the
application of the laws of any

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       11
<PAGE>

jurisdiction other than the State of California, and (ii) except that the rights
of the parties to resolve by arbitration any dispute arising between them
regarding the subject matter of this Agreement shall not be governed by the
California arbitration act or international arbitration act (Cal. Code of Civ.
Proc. (S) 1280 et seq. and 1297.11 et seq.) but rather by the United States
Arbitration Act (9 U.S.C. (S)(S) 1-14, 201-208).

     11.2 Dispute Resolution.  In the event of any controversy or claim arising
out of, relating to or in connection with any provision of this Agreement, the
Parties shall try to settle their differences amicably and in good faith between
themselves first, by referring the disputed matter to the respective heads of
research of each Party and, if not resolved by the research heads, by referring
the disputed matter to the respective Chief Executive Officer of each Party.  In
the event such executives are unable to resolve such dispute within such thirty
(30) day period, either Party may invoke the provisions of Section 11.3.

     11.3 Arbitration.  Upon failure to resolve any controversy or claim
arising out of, relating to or in connection with any provision of this
Agreement using the dispute resolution procedure described in Section 11.2, and
except as provided in Section 11.3(c) below, any dispute, controversy or claim
arising out of or relating to the validity, construction, enforceability or
performance of this Agreement, including disputes relating to alleged breach or
to termination of this Agreement, other than disputes which are expressly
prohibited herein from being resolved by this mechanism, shall be settled by
binding Alternative Dispute Resolution ("ADR") in the manner described below:

          (a)  If a party intends to begin an ADR to resolve a dispute, such
party shall provide written notice (the "ADR Request") to counsel for the other
party informing such other party of such intention and the issues to be
resolved.  From the date of the ADR Request and until such time as any matter
has been finally settled by ADR, the running of the time periods contained in
Article 10 as to which a party must cure a breach of this Agreement shall be
suspended as to the subject matter of the dispute.

          (b)  Within ten (10) business days after the receipt of the ADR
Request, the other party may, by written notice to the counsel for the party
initiating ADR, add additional issues to be resolved.

          (c)  Any dispute regarding the validity or enforceability of a patent
or trademark applicable to a product shall be submitted to a court of competent
jurisdiction in the country in which such patent or trademark right exists.

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       12
<PAGE>

     11.4 Procedure. The ADR shall be conducted pursuant to JAMS/ENDISPUTE
Rules A and C then in effect.  Notwithstanding those rules, the following
provisions shall apply to the ADR hereunder.

          (a)  Arbitrator.  The arbitration shall be conducted by a panel of
three arbitrators ("the Arbitrators").  The Arbitrators shall be selected from a
pool of retired independent federal judges to be presented to the parties by
JAMS/ENDISPUTE.  Neither party shall engage in ex parte contact with the
arbitrator.

          (b)  Proceedings. The time periods set forth in the JAMS/ENDISPUTE
rules shall be followed, unless a party can demonstrate to the Arbitrator that
the complexity of the issues or other reasons warrant the extension of one or
more of the time tables. The Arbitrator shall not award punitive damages to
either party and the parties shall be deemed to have waived any right to such
damages.  The Arbitrator shall apply the Federal Rules of Evidence to the
hearing.  The proceeding shall take place in Honolulu, Hawaii in the English
language.  The fees of the Arbitrators and JAMS/ENDISPUTE shall be paid by the
losing party, which shall be designated by the Arbitrator.  If the Arbitrator is
unable to designate a losing party, it shall so state and the fees shall be
split equally between the parties.

          (c)  Award.  The Arbitrator is empowered to award any remedy allowed
by law, including money damages, prejudgment interest and attorneys' fees, and
to grant final, complete, interim, or interlocutory relief, including injunctive
relief but excluding punitive damages.

     11.5 Confidentiality.  The ADR proceeding, the existence of any dispute
submitted to ADR, and the award shall be confidential and the Panel shall issue
appropriate protective orders to safeguard each party's Confidential
Information.  Except as required by law or in connection with the enforcement of
an award hereunder, no party shall disclose (or instruct the Panel to disclose)
such Confidential Information without prior written consent of each other party.

     11.6  Judicial Enforcement.  The parties agree that judgment on any
arbitral award issued pursuant to this Article 11 shall be entered in the United
States District Court for the Northern District of California or, in the event
such court does not have subject matter jurisdiction over the dispute in
question, such judgment shall be entered in the Superior Court of the State of
California, in the County of San Mateo.

12.  Miscellaneous.

     12.1 Notices.  All notices required or permitted to be given under this
Agreement shall be in writing and shall be mailed by registered or certified
mail, postage prepaid, addressed to the signatory to whom such notice is
required or permitted to be given and transmitted by facsimile to the number
indicated below.  All notices shall be deemed to have been given when mailed, as
evidenced by the postmark at the point of mailing, or transmitted by facsimile.

     All notices to Sankyo shall be addressed as follows:

     Sankyo Company, Ltd.

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE sECURITIES ACT OF 1933, AS
AMENDED.

                                       13
<PAGE>

     2-58, Hiromachi 1-chome
     Shinagawa-ku
     Tokyo 140-8710
     JAPAN
     Attention:  Dr. Hiroshi Fukumi
     Fax: 81-3-5436-8569

     with a copy to:

     Sankyo Company, Ltd.
     2-58, Hiromachi 1-chome
     Shinagawa-ku
     Tokyo 140-8710
     JAPAN
     Attention:  Dr. Hidenori Shimotsu
     Fax:  81-3-5436-8561

     All notices to Telik shall be addressed as follows:

     Telik, Inc.
     750 Gateway Boulevard
     South San Francisco, California 94080
     U.S.A.
     Attention:  President
     Fax: (650) 244-9388

     with a copy to:

     Cooley Godward LLP
     Five Palo Alto Square
     3000 El Camino Real
     Palo Alto, California 94306
     U.S.A.
     Attention: Robert L. Jones, Esq.
     Fax:  (650) 857-0663

     Any Party may, by written notice to the other, designate a new addressee,
address or facsimile number to which notices to the Party giving the notice
shall thereafter be mailed or faxed.

     12.2 Force Majeure.  No Party shall be liable for any delay or failure of
performance to the extent such delay or failure is caused by circumstances
beyond its reasonable control and that by the exercise of due diligence it is
unable to prevent, provided that the Party claiming excuse uses its best efforts
to overcome the same.

     12.3 Entirety Of Agreement.  This Agreement embodies the entire, final and
complete agreement and understanding between the Parties and replaces and
supersedes all prior

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
    BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
    EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE sECURITIES ACT OF 1933, AS
    AMENDED.

                                       14
<PAGE>

discussions and agreements between them with respect to its subject matter
except as expressly stated herein. No modification or waiver of any terms or
conditions hereof shall be effective unless made in writing and signed by a duly
authorized officer of each Party.

     12.4  Non-Waiver.  The failure of a Party in any one or more instances to
insist upon strict performance of any of the terms and conditions of this
Agreement shall not constitute a waiver or relinquishment, to any extent, of the
right to assert or rely upon any such terms or conditions on any future
occasion.

     12.5  Disclaimer Of Agency.  Neither Party is, or will be deemed to be, the
legal representative or agent of the other, nor shall either Party have the
right or authority to assume, create, or incur any third party liability or
obligation of any kind, express or implied, against or in the name of or on
behalf of another except as expressly set forth in this Agreement.

     12.6  Severability.  If a court of competent jurisdiction declares any
provision of this Agreement invalid or unenforceable, or if any government or
other agency having jurisdiction over either Telik or Sankyo deems any provision
to be contrary to any laws, then that provision shall be severed and the
remainder of the Agreement shall continue in full force and effect.  To the
extent possible, the Parties shall revise such invalidated provision in a manner
that will render such provision valid without impairing the Parties' original
interest.

     12.7  Affiliates; Assignment.  Except as otherwise provided in this Section
12.7, neither Party may assign its rights or obligations under this Agreement
without the prior written consent of the other Party, such consent not to be
unreasonably withheld, except that a Party may assign its rights or obligations
to a third party in connection with the merger, consolidation, reorganization or
acquisition of stock or assets affecting substantially all of the assets or
actual voting control of the assigning Party.  This Agreement shall be binding
upon the successors and permitted assigns of the Parties. Any attempted
delegation or assignment not in accordance with this Section 12.7 shall be of no
force or effect.

     12.8  Headings.  The headings contained in this Agreement have been added
for convenience only and shall not be construed as limiting.

     12.9  Limitation Of Liability and Indemnification.  No Party shall be
liable to another for indirect, incidental, consequential or special damages,
including but not limited to lost profits, arising from or relating to any
breach of this Agreement, regardless of any notice of the possibility of such
damages.  In no event shall Telik be liable for any use by Sankyo of the
Provided Compounds.  Sankyo hereby agrees to indemnify, defend and hold Telik
harmless from damages for any loss, claim, injury or liability or whatsoever
kind or nature, which may arise from Sankyo's use, handling or storage of the
Provided Compounds.

     12.10 Counterparts.  This Agreement may be executed in one or more
counterparts, each of which shall be an original and all of which shall
constitute together the same document.

     12.11 English Language.  This Agreement has been prepared in the English
language and shall be construed in the English language.

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
    BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
    EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
    AMENDED.

                                       15
<PAGE>

     12.12 Further Assurances. Each party hereby agrees to execute, acknowledge
and deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

     IN WITNESS WHEREOF, the parties have by duly authorized persons, executed
this Agreement, as of the date first above written.

<TABLE>
<CAPTION>
Sankyo Company, Ltd.                  Telik, Inc.
<S>  <C>                           <C>
By:    /s/ Tetsuo Hiraoka             By:    /s/ Reinaldo A. Gomez
       ----------------------------          ----------------------------------
Title: Director, Research Institute   Title: Vice President Corporate Alliances
       ----------------------------          ----------------------------------
Date:  March 23, 1999                 Date:  March 24, 1999
       ----------------------------          ----------------------------------
</TABLE>

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
    BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
    EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
    AMENDED.

                                       16
<PAGE>

                                    APPENDIX

                          SELECTED TARGETS AND ASSAYS

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       17
<PAGE>

                                    APPENDIX

                Targets, Assays and Criteria of Active Molecules
                                    5/13/99

[*]

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       18
<PAGE>

September 30, 1999

Dr. Yoshiki Matsui
Vice Director, Research Planning Department
and
Dr. Hidenori Shimotsu
Research Planning Department
Sankyo Co., Ltd.
2-58, Hiromachi 1-chome
Shinagawa-ku, Tokyo 140
Japan

Dear Dr. Matsui and Dr. Shimotsu:

     Reference is made to that certain Agreement dated as of March 24, 1999
     between Sankyo Company, Ltd. and Telik, Inc. (the "Agreement"; capitalized
     terms used and not otherwise defined herein shall have the meanings
     ascribed to such terms in the Agreement).  Subject to your agreement
     herewith, as of the date indicated below, the notices provided to Sankyo
     stated in Article 12.1 of the Agreement shall be addressed as follows:

          Sankyo Company, Ltd.
          2-58, Hiromachi 1-chome
          Shinagawa-ku
          Tokyo 140
          JAPAN
          Attention: Dr. Hidenori Shimotsu
          Fax: 81-3-5436-8561

     with a copy to:

          Sankyo Company, Ltd.
          2-58, Hiromachi 1-chome
          Shinagawa-ku
          Tokyo 140
          JAPAN
          Attention: Dr. Yoshiki Matsui
          Fax: 81-3-5436-8561

Page 2
September 30, 1999

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       19
<PAGE>

     If you are in agreement with the foregoing, please execute this letter
agreement where indicated below whereupon it will become an agreement between us
on the terms indicated above.

                                       Sincerely,

                                       TELIK, INC.

                                       By:     /s/ Reinaldo F. Gomez
                                               ----------------------------
                                       Name:   Reinaldo F. Gomez
                                               ----------------------------
                                       Title:  VP Corporate Alliance
                                               ----------------------------

Accepted and Agreed to
this ____ of October, 1999.

 SANKYO COMPANY, LTD.

 By:     /s/ Yukio Sughnura
        ----------------------------
 Name:   Yukio Sughnura, Ph.D.
        ----------------------------
 Title:  Senior Director
        ----------------------------
        Research Planning Department
        ----------------------------
        Sankyo Co., Ltd.
        ----------------------------

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS
AMENDED.

                                       20
<PAGE>

                                    APPENDIX

                Targets, Assays and Criteria of Active Molecules
                                Ammended 2/16/00

Selected Targets
----------------

[*]

Substitute Selected Targets
---------------------------

[*]

[*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE sECURITIES ACT OF 1933, AS
AMENDED.

                                       21<PAGE>

Certain confidential information contained in this document, marked by brackets,
has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                                                    EXHIBIT 10.6

                            COLLABORATION AGREEMENT

     This Collaboration Agreement (the "Agreement") is entered into as of the
20th day of December, 1996 (the "Effective Date") by and between Sanwa Kagaku
Kenkyusho Co., Ltd., a Japanese corporation with its offices at 35 Higashi
Sotobori-cho, Higashi-ku Nagoya, 461, Japan ("Sanwa") and Terrapin Technologies,
Inc., a Delaware corporation with its offices at 750 Gateway Boulevard, South
San Francisco, California 94080, U.S.A. ("Terrapin").  Sanwa and Terrapin are
sometimes referenced in this Agreement individually as a "Party" and
collectively as the "Parties."

                                   Recitals

     Whereas, Terrapin has knowledge of a novel target in the insulin signal
transduction pathway and compounds that activate the insulin receptor; and

     Whereas, Terrapin possesses a library of compounds and is able to determine
the affinity of each compound versus Terrapin's reference proteins employed in
Terrapin's proprietary TRAP (TM) technology; and

     Whereas, Sanwa is engaged in the research, development, marketing,
manufacture and distribution of therapeutic pharmaceutical products; and

     Whereas, Terrapin and Sanwa desire to enter into a collaborative program to
research and discover compounds that act through activation of the insulin
signal transduction pathway for purposes of the treatment of diabetes mellitus
or insulin resistance; and

     Whereas, Terrapin and Sanwa have entered into a binding letter of intent,
dated November 6, 1996, setting forth their intent to enter into a definitive
agreement with respect to such collaborative program; and

     Whereas, Terrapin and Sanwa will enter into a separate agreement under
which Terrapin shall utilize its proprietary TRAP (TM) technology to evaluate
certain of Sanwa's drug targets for the purpose of identifying compounds for
pharmaceutical development.

     Now, Therefore, in consideration of the foregoing and the covenants and
premises contained in this Agreement, the Parties agree as follows:

                                       1
<PAGE>

                                   Article 1

                                  Definitions

     As used herein, the following terms shall have the following meanings:

     1.1  "Affiliate" shall mean any company or entity controlled by,
controlling, or under common control with a Party hereto and shall include
without limitation any company fifty percent (50%) or more of whose voting stock
or participating profit interest is owned or controlled, directly or indirectly,
by a Party, and any company which owns or controls, directly or indirectly,
fifty percent (50%) or more of the voting stock of a Party.

     1.2  "Clinical Candidate" shall mean any compound identified under the
Research Program which the RMC determines may be useful in the Field.

     1.3  "Confidential Information" shall mean all information, inventions,
know-how or data of either Party disclosed pursuant to, or in contemplation of,
this Agreement in written, graphic or electronic form if marked as confidential
or in oral form if designated as confidential and confirmed in writing promptly
after oral disclosure, including, without limitation, (i) information regarding
the Research Program, Clinical Candidates, Licensed Products, and other matters
material to this Agreement or the business of the disclosing Party, including
manufacturing, marketing, financial, personnel, scientific and other business
information and plans, and (ii) the material terms of this Agreement.

     1.4  "Control" shall mean possession of the ability to grant the licenses
as provided for herein without violating the terms of any agreement or
arrangement with a third party.

     1.5  "FDA" shall mean the United States Food and Drug Administration.

     1.6  "Field" shall mean compounds that act through activation of the
insulin signal transduction pathway for the treatment of diabetes mellitus or
insulin resistance in humans.

     1.7  "IND" shall mean an Investigational New Drug Application as defined in
the FDA regulations, as such regulations may be amended from time to time.

     1.8  "Letter of Intent" shall mean that Letter of Intent between the
Parties dated November 6, 1996.

     1.9  "License Agreement" shall mean the license agreement referenced in
Article 3.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       2
<PAGE>

     1.10  "Licensed Product" shall have the meaning assigned to it in the
License Agreement.

     1.11  "NDA" shall mean a New Drug Application as defined in the United
States Federal Food, Drug and Cosmetic Act and applicable regulations
thereunder, as amended from time to time.

     1.12  "Phase I" shall mean the clinical trials which are the equivalent in
the relevant country of the Sanwa Territory to that phase of clinical
development of pharmaceutical products defined as "Phase I" in FDA regulations
as amended from time to time.

     1.13  "Phase II" shall mean the clinical trials which are the equivalent in
the relevant country of the Sanwa Territory to that phase of clinical
development of pharmaceutical products defined as "Phase II" in FDA regulations
as amended from time to time.

     1.14  "Phase III" shall mean the clinical trials which are the equivalent
in the relevant country of the Sanwa Territory to that phase of clinical
development of pharmaceutical products defined as "Phase III" in FDA regulations
as amended from time to time.

     1.15  "Research Plan" shall have the meaning set forth in Section 2.1.

     1.16  "Research Program" shall have the meaning set forth in Section 2.1.

     1.17  "Research Term" shall have the meaning set forth in Section 2.1.

     1.18  "RMC" shall mean the Research Management Committee established by the
Parties pursuant to Section 2.2.

     1.19  "Sanwa Technology" shall mean all technology, inventions,
information, data, know-how, patents and patent applications (including any
divisions, continuations, continuations-in-part, reissues, extensions, renewals,
supplementary protection certificates and foreign counterparts thereof) that are
useful in the Field and which Sanwa owns or Controls during the term of this
Agreement.

     1.20  "Sanwa Territory" shall mean Japan, Korea, Taiwan and the People's
Republic of China.

     1.21  "Terrapin Technology" shall mean all technology, inventions,
information, data, know-how, patents and patent applications (including any
divisions, continuations, continuations-in-part, reissues, extensions, renewals,
supplementary

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       3
<PAGE>

protection certificates and foreign counterparts thereof) that are useful in the
Field and which Terrapin owns or Controls during the term of this Agreement.

                                   Article 2

                     Research Program Scope and Governance

     2.1  Research Program; Research Plan.  The Parties will participate in a
collaborative program (the "Research Program") to research and discover novel
compounds for use in the Field.  The Research Program shall commence on the
Effective Date and continue until the [ * ] unless earlier terminated pursuant
to Section 9.2 and 9.3 or extended by mutual written agreement of the Parties.
The period of time during which the Research Program is in effect shall be the
"Research Term."  The Research Program shall be conducted pursuant to a detailed
research plan attached hereto as Exhibit A, which may be modified from time to
time by the RMC (the "Research Plan").  Terrapin shall commence the Research
Program promptly upon execution of this Agreement.  Each Party shall devote
commercially reasonable efforts to its obligations under the Research Program,
consistent with the efforts it devotes to its own research programs of
comparable market potential.

     2.2  Research Management Committee Formation and Procedure.  Within [ * ]
of the Effective Date, the Parties will form a Research Management Committee
(the "RMC") having the functions and powers described in Section 2.3.  The RMC
will be comprised of [ * ] from each of Terrapin and Sanwa.  All decisions of
the RMC must be unanimously approved by the members of the RMC.  The RMC shall
agree, in good faith, upon the chairperson of the RMC, the time and place of
meetings of the RMC, substitutions for RMC members, qualifications of RMC
members, and other similar matters.  Within [ * ] days after each meeting, the
RMC will provide the Parties with a written report describing the status of the
Research Program, issues requiring resolution and resolutions of previously
reported issues, all in reasonable detail.  In the event the RMC is unable to
reach a decision concerning the designation of a Clinical Candidate, such
matters will be resolved in accordance with the provisions of Section 11.2.

     2.3  Research Management Committee Functions and Powers.  The RMC shall:
(i) encourage and facilitate ongoing cooperation between the Parties, (ii)
periodically review the progress of the Research Program, including all
screening results and other work done and new developments in the Field, and
propose changes to the Research Plan based upon such review, (iii) designate
compounds as Clinical Candidates from time to time based upon the results of the
Research Program, (iv) allocate tasks and coordinate activities required to
perform the Research Program, (v) monitor progress of the Research Program and
the Parties' diligence in carrying out their responsibilities

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       4
<PAGE>

thereunder, and (vi) carry out any other duties and responsibilities described
for it in this Agreement.

     2.4  Research Liaison.  Each Party shall appoint a qualified representative
(each a "Research Liaison") to be the liaison to the other Party and to the RMC.
The Research Liaisons shall serve as the principal point of communication
between the parties and shall confer together at least monthly concerning the
details of the Research Program.

     2.5  Basic Responsibilities of Terrapin

          2.5.1  Terrapin will be responsible for providing all infrastructure
[*] necessary for conducting [ * ] Phase 1 of the Research Plan, relating to
identification and selection of advanced lead compounds and Phase 2 of the
Research Plan, relating to identification and selection of Clinical Candidates.
If Terrapin shall choose to develop or have developed the same Clinical
Candidate outside the Sanwa Territory, then Terrapin will also be responsible
for providing all infrastructure [ * ] necessary for and conducting [ * ], Phase
3 of the Research Plan, relating to all IND enabling work for Clinical
Candidates, except that portion of Phase 3 work identified therein as uniquely
required for an IND application in Japan.

          2.5.2  All research and development work to be performed by Terrapin
pursuant to this Agreement shall be performed in a timely manner and meet all
FDA quality standard requirements.  In performing such work and without limiting
the obligations set forth in this Section 2.5, Terrapin shall provide [ * ] a
sufficient number of full-time, trained, experienced researchers, chemists,
pharmacologists, biologists and technicians and other specialists competent and
qualified to perform the work to be performed pursuant to this Agreement.

     2.6  Use of Third Parties by Terrapin.  During the term of this Agreement,
Terrapin may utilize the services of outside consultants or third parties in
connection with performing its research and development work provided that
Terrapin assumes full responsibility and liability for such third parties.

     2.7  Basic responsibilities of Sanwa.  Sanwa will be responsible for
providing all infrastructure [ * ] necessary for and conducting [ * ] that
portion of Phase 3 of the Research Plan identified therein as uniquely required
for an IND application in Japan with respect to Clinical Candidates for which
Sanwa has sent or plans to send a Development and Commercialization Notice to
Terrapin and which Terrapin chooses not to develop or have developed outside of
Japan.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       5
<PAGE>

     2.8  Cooperation; Reports; Reciprocal Sharing of Data.

          2.8.1  Each Party will cooperate with each other in conducting the
Research Program.

          2.8.2  The Parties shall make available and disclose to one another,
on a quarterly basis through the RMC, all results of the work conducted pursuant
to Phase 1 and Phase 2 of the Research Program.

          2.8.3  Terrapin shall make available and disclose to Sanwa, on a [ * ]
basis through the RMC, all work related to Phase 3 of the Research Program for
which Terrapin is responsible pursuant to Section 2.5.  Terrapin shall also make
available to Sanwa data within the Field relevant to the Research Program
arising from arrangements between Terrapin and third parties similar to this
Agreement but only to the extent, and upon such terms, as such third party shall
agree including, if necessary, an agreement by Sanwa to provide similar
information to such third party upon a reciprocal basis.  Without limiting the
generality of the foregoing, Terrapin agrees to use its reasonable efforts in
good faith to cause any third party having rights to Clinical Candidates outside
the Sanwa Territory to provide the results of tests and other work corresponding
to Phase 3 of the Research Plan to Sanwa for such Clinical Candidates.

          2.8.4  Sanwa shall disclose all Phase 3 work relating to Clinical
Candidates to Terrapin.  Terrapin may use such information solely for the
purposes of the Research Program and shall not use it for any other purpose or
disclose it to any third party unless Sanwa agrees to the terms of such use or
disclosure (which may include cost reimbursement for all or a portion of the
Phase 3 work conducted by Sanwa or on Sanwa's behalf by a third party).

     2.9  Supply of Preclinical and Clinical Material.  Terrapin will provide
Sanwa [ * ] of Clinical Candidate requested by Sanwa.  Such materials will be
produced using a process to be developed by Terrapin which complies with then
current good manufacturing processes in accordance with the requirements of the
FDA; provided, however, that the parties may hereafter agree that Sanwa will
produce some or all of the Clinical Candidate material.  Sanwa will notify
Terrapin of the quantities and delivery dates of the material needed and pay
Terrapin [ * ] for such material, all according to such reasonable procedures as
the parties shall hereafter agree.

                                   Article 3

         Election to Pursue Further Development and Commercialization

     3.1  Development and Commercialization Notice.  At any time during the
Research Term or within [ * ] thereafter, Sanwa may provide written notice (the

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       6
<PAGE>

"Development and Commercialization Notice") to Terrapin of its intention to
develop a Clinical Candidate for use in the Field and, if results of the human
clinical studies justify, to prepare and file the Japanese equivalent of an NDA
on such Clinical Candidate for use in the Field.  Such notice shall be in the
form attached hereto as Exhibit B and shall be made prior to the filing of the
Japanese equivalent of an IND by Sanwa for such Clinical Candidate.  Upon
Terrapin's receipt of the first Development and Commercialization Notice,
Terrapin and Sanwa shall promptly enter into a license agreement with respect to
the Clinical Candidate described in such Development and Commercialization
Notice, upon substantially the terms set forth in the form of License Agreement
set forth in Exhibit C attached hereto.  For each subsequent Clinical Candidate
which Sanwa elects to develop and commercialize as set forth in this Article 3,
Sanwa shall provide a new Development and Commercialization Notice to Terrapin
and, upon Terrapin's receipt of such Development and Commercialization Notice,
such Clinical Candidate(s) shall be added to Exhibit 1 to the License Agreement
and shall be regarded as a Licensed Product for all purposes of the License
Agreement.

     3.2  Discussion Concerning Third Party Program in Territories.  In the
event Sanwa shall not deliver a Development and Commercialization Notice as
provided in Section 3.1 with respect to at least [ * ] after the termination of
this Agreement Terrapin shall be free to enter into an agreement with a third
party in the Sanwa Territory pertaining to the Field without any obligation or
liability to Sanwa other than as provided in this Section 3.2; provided,
however, that at least [ * ] prior to entering into any such agreement, Terrapin
shall notify Sanwa of its intention to do so and discuss with Sanwa in good
faith during such period any proposal Sanwa may make concerning a further
arrangement relating to the Field and Sanwa Territory.  Terrapin's obligation to
provide such notice to Sanwa and to discuss any such proposal with Sanwa shall
survive the termination of this Agreement for a period of [ * ]

     3.3  Rights with Respect to Clinical Candidates Not Selected.  With respect
to a Clinical Candidate which enters Phase 3 of the Research Program but for
which Sanwa did not give a Development and Commercialization Notice as provided
in Section 3.1 prior to [ * ] if, at any time during the first [ * ] thereafter,
Terrapin determines it wishes to grant rights outside the Field to such Clinical
Candidate to a third party, then, provided Sanwa has entered into the License
Agreement with respect to at least one Clinical Candidate, Terrapin will first
provide notice of its intention to Sanwa.  If within [ * ] of receipt of
Terrapin's notice, Sanwa provides Terrapin a Development and Commercialization
Notice with respect to such Clinical Candidate, then such Clinical Candidate
shall be added to Exhibit I to the License Agreement and shall be regarded as a
Licensed Product for all purposes of the License Agreement.  If, at or before
the end of such period, Sanwa does not provide a Development and
Commercialization Notice with respect to such Clinical Candidate, then Terrapin
shall have no further obligation or

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       7
<PAGE>

liability to Sanwa with respect to such Clinical Candidate and shall be free to
enter into one or more transactions with third parties with respect thereto.

     3.4  Royalty Rates in Certain Countries.  The parties intend that the Sanwa
Territory shall include Korea, Taiwan and the People's Republic of China, in
addition to Japan, but have not as of the Effective Date of this Agreement
agreed to royalty rates for such countries.  As soon as practicable after the
Effective Date of this Agreement but not later than the Effective Date of the
License Agreement, the parties shall meet and agree on the royalty rates for
such countries.  Upon such agreement each such country and agreed rate shall be
included in Appendix 2 to the License Agreement.  In the event, however, that
the parties shall fail to agree on the royalty rate for one or more of such
countries, then such country shall not be included in Appendix 2 to the License
Agreement and Sanwa shall have no rights hereunder or under the License
Agreement with respect to such country.

                                   Article 4

                                License Grants

     4.1  Grant by Terrapin. Terrapin hereby grants to Sanwa, during the
Research Term, a non-exclusive, worldwide, royalty-free license under the
Terrapin Technology for the sole purpose of allowing Sanwa to carry out its
responsibilities under the Research Program.  Sanwa may grant a sublicense under
the foregoing license.  In the event Sanwa grants a sublicense under the
preceding sentence, it shall provide prior written notice to Terrapin of the
name of the sublicensee and the purposes for such sublicense.

     4.2  Grant by Sanwa.  Sanwa hereby grants to Terrapin, during the Research
Term, a non-exclusive, worldwide, royalty-free license under the Sanwa
Technology for the sole purpose of allowing Terrapin to carry out its
responsibilities under the Research Program.  Terrapin may grant a sublicense
under the foregoing license.  In the event Terrapin grants a sublicense under
the preceding sentence, it shall provide prior written notice to Sanwa of the
name of the sublicensee and the purposes for such sublicense.

     4.3  Documentation of License Rights.  To the extent necessary to permit a
party to carry out its responsibilities under the Research Program, the licensor
of technology under Sections 4.1 or 4.2 above, promptly after request by the
licensee, shall provide a complete and organized set of written materials
embodying the requested technology.  The licensor providing those materials may
provide them in their original language.  The licensee may from time to time
convey questions to the licensor regarding the subject of the technology, and
the licensor shall cause its technical personnel to respond promptly and fully
to those questions without additional charge to the licensee.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       8
<PAGE>

     4.4  Exclusive Collaboration.  Each party to this Agreement covenants and
agrees that the Research Program shall be its sole and exclusive activity within
the Field in the Sanwa Territory during the term of this Agreement.  Terrapin
covenants and agrees that during the term of this Agreement, it will not license
compounds to third parties in the Sanwa Territory where the development of such
compounds is directed toward the Field.

                                   Article 5

                             Financial Provisions

     5.1  Collaboration Agreement Signing Fee.  Within five (5) business days
after the Effective Date, Sanwa shall make a nonrefundable payment to Terrapin
of [ * ]

     5.2  Equity Investment in Terrapin.

          5.2.1  Stock Purchase Agreement.  Simultaneous with the execution of
this Agreement, the Parties are entering into a Stock Purchase Agreement, in the
form attached hereto as Exhibit D ("Stock Purchase Agreement").

          5.2.2  [ * ]

     5.3  Research Payments.  In support of Terrapin's activities under the
Research Program, Sanwa shall pay Terrapin (i) [ * ] within five (5) business
days after the [ * ] (ii) [ * ] within five (5) business days after the [ * ]
and (iii) [ * ] within five (5) business days after the [ * ]  In the event this
Agreement shall be terminated within a [ * ] period following any of the
foregoing payment dates, then Terrapin shall [ * ] under this Section 5.3 in
respect of such payment date.  Such [ * ] shall equal [ * ] where X equals [ * ]

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       9
<PAGE>

     5.4  Milestone Payments to Terrapin.  Sanwa shall make the following
nonrefundable payments to Terrapin, within [ * ] after the occurrence of the
following events:

==================================================================
MILESTONE EVENT                                  AMOUNT OF PAYMENT
------------------------------------------------------------------
(1)  [ * ]                                             [ * ]
------------------------------------------------------------------
(2)  [ * ]                                             [ * ]
------------------------------------------------------------------
(3)  [ * ]                                             [ * ]
------------------------------------------------------------------
(4)  [ * ]                                             [ * ]
------------------------------------------------------------------
(5)  [ * ]                                             [ * ]
------------------------------------------------------------------
(6)  [ * ]                                             [ * ]
==================================================================

Each of the foregoing payments shall be made only once regardless of the number
of products licensed to Sanwa.

     5.5  Japan Withholding Taxes.

          5.5.1   Payments under Section 5.1 and Section 5.3. Any withholding
taxes to be levied on the payments to Terrapin under Section 5.1 and Section 5.3
by any tax authority in Japan shall be borne by [ * ] Terrapin agrees to make
reasonable good faith efforts to assist Sanwa in the characterization of the
payments under Section 5.3 as research expenses.

          5.5.2   Other Payments.  Except as set forth in Section 5.5.1, any
income, withholding or other taxes to be levied on the income of Terrapin by any
tax authority by reason of the execution of, or any performance under, this
Agreement, other than as provided in Section 5.5.1, shall be borne by Terrapin.
In the event that Sanwa deducts such tax from the amount of the income to be
remitted to Terrapin in order to pay such tax authority on behalf of Terrapin,
Sanwa shall send to Terrapin, in due course, reasonable evidence showing the
payment of such tax.

     5.6  Payments.  All payments to be made by either Party to the other Party
hereunder, except as otherwise provided herein, shall be remitted by wire
transfer to the

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       10
<PAGE>

account of the other Party with such bank as may be designated by the other
Party, and shall be made in U.S. dollars.

                                   Article 6

                             Intellectual Property

     6.1  Ownership Of Pre-Existing Technology And Technology Developed Outside
Of The Research Program.  Each Party shall remain the sole owner of all of its
respective technology, compounds, discoveries and inventions which are either
(i) in existence as of the Effective Date or (ii) made outside of the Research
Program, subject to the license grants set forth in Article 4 and any license
granted under the License Agreement.

     6.2  Ownership Of Research Program Technology.  Inventions or discoveries
made, and materials and information created solely by one Party in the course of
the Research Program shall be owned solely by such Party, subject to the license
grants set forth in Article 4 and any license granted under the License
Agreement.  Inventions or discoveries made, and materials and information
created jointly by the Parties in the course of the Research Program shall be
owned jointly by the Parties.  In all cases, inventorship under the Research
Program shall be determined in accordance with the United States patent laws.

     6.3  Patent Prosecution.

          6.3.1    Under the Research Program.  The RMC shall consider and
recommend to each party from time to time which inventions arising from the
Research Program shall be the basis of patent applications and which shall be
maintained as trade secrets.  Patent applications and patents for inventions
arising under the Research Program which are owned by one Party pursuant to
Section 6.2 shall be prosecuted and maintained by the Party owning such
invention, at such Party's option and its own expense.  Terrapin shall be
responsible, on a worldwide basis, for filing and prosecuting patent
applications for, and maintaining patents on, jointly owned inventions arising
under the Research Program pursuant to Section 6.2 (the "Joint Research Program
Patents"), using counsel of its choice, and at its own expense.  Terrapin shall
confer with Sanwa on the content of all filings with the United States Patent
and Trademark Office (or the foreign equivalent), and, taking into account
Sanwa's knowledge and expertise with respect to filing and maintaining patents
in the Sanwa Territory, shall provide Sanwa with the opportunity to review the
content of such filings prior to their submission to such authorities and give
due consideration to its recommendations thereto.

          6.3.2  Under the License Agreement.  In the event that Sanwa provides
a Development and Commercialization Notice to Terrapin regarding a Clinical
Candidate

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       11
<PAGE>

and the Parties enter into a License Agreement with respect to the Clinical
Candidate described in such Notice, Sanwa shall, at its own expense, assume
responsibility for filing and prosecuting in the Sanwa Territory patent
applications for, and maintaining patents on, such Clinical Candidate and/or
Licensed Products containing such Clinical Compound or derived therefrom. In
such event, Terrapin shall transmit to Sanwa all information reasonable and
appropriate then in its possession relating to such patent application or patent
and execute all consents or other filings reasonably necessary to permit Sanwa
to assume such responsibility.

          6.3.3  Back-up Prosecution.  In the event that a Party decides not to
proceed with prosecuting a patent application for, or maintaining a patent on,
an invention for which it is responsible under this Section 6.3 in any country
of the Sanwa Territory, it shall give the other Party sixty (60) days notice
before any relevant deadline and transmit all information reasonable and
appropriate relating to such patent application or patent, and such other Party
shall have the right to pursue, at its own expense, prosecution of such
application for, or maintenance of, such patent.

     6.4  Infringement.  The License Agreement shall provide for enforcement of
Licensed Patents (as defined in the License Agreement) and defense against third
party claims of infringement, and such matters will be governed thereby.  If any
patent infringement matters arise prior to execution of the License Agreement,
the Parties will discuss in good faith the manner in which they will proceed to
address such issues, in accordance with the provisions set forth in Section 5.3
of the License Agreement attached hereto as Exhibit C.

     6.5  Disclosure Of Inventions.  Terrapin and Sanwa will disclose promptly
to each other all discoveries or inventions made pursuant to the Research
Program, including discoveries or inventions made by consultants or contractors
of Terrapin and Sanwa pursuant to the Research Program, prior to any public
disclosure or filing of patent applications and allowing sufficient time for
comment and review by the other Party; provided, however, review and comment
shall be subject to the time limitations necessitated as a practical matter by
Japan's first to file patent system.

                                   Article 7

                        Representations and Warranties

     7.1  Representations And Warranties.

          7.1.1  Both Parties.  Each Party represents and warrants to the other
that:

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       12
<PAGE>

               (a)  Corporate Power.  It is duly organized and validly existing
under the laws of its state or country of incorporation, and has full corporate
power and authority to enter into this Agreement and to carry out the provisions
hereof.

               (b)  Due Authorization.  It is duly authorized to execute and
deliver this Agreement and to perform its obligations hereunder, and the person
executing this Agreement on its behalf has been duly authorized to do so by all
requisite corporate action.

               (c)  Binding Agreement.  This Agreement is legally binding upon
it and enforceable in accordance with its terms. The execution, delivery and
performance of this Agreement by it does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a party or by which
it may be bound, nor violate any material law or regulation of any court,
governmental body or administrative or other agency having jurisdiction over it.

               (d)  Grant of Rights; Maintenance of Agreements.  It has not, and
will not during the term of this Agreement, grant any right to any third party
which would conflict with the rights granted to the other Party hereunder. It
has (or will have at the time performance is due) maintained and will maintain
and keep in full force and effect all agreements necessary to perform its
obligations hereunder.

               (e)  Validity.  It is aware of no action, suit or inquiry or
investigation instituted by any governmental agency which questions or threatens
the validity of this Agreement.

               (f)  [ * ]  To the best of its knowledge, it has all right, power
and authority to perform its obligations under, and [ * ] To the best of its
knowledge, there are [ * ]

               (g)  Accuracy of Information.  All documentation and other
information conveyed by one Party to another hereunder or in connection
herewith, was, at the time it was conveyed or provided, accurate and complete in
light of the purposes for which it was intended.

          7.1.2  By Terrapin.  The compounds identified by Terrapin for use in
the Research Program and described by Terrapin to Sanwa act at least in part
through activation of the insulin signal transduction pathway.

     7.2  Disclaimer Concerning Technology.  EXCEPT AS SET FORTH IN SECTION 7.1
ABOVE, THE TECHNOLOGY PROVIDED BY EACH PARTY HEREUNDER IS PROVIDED "AS IS" AND
EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       13
<PAGE>

IMPLIED, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY
RIGHTS OF THIRD PARTIES OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE
PRACTICES, IN ALL CASES WITH RESPECT THERETO.  Without limiting the generality
of the foregoing, each Party expressly does not warrant (i) the success of any
study or test commenced under the Research Program or (ii) the safety or
usefulness for any purpose of the technology it provides hereunder.

     7.3  Disclaimer Concerning Compounds.  EXCEPT AS SET FORTH IN  SECTION 7.1
ABOVE, THE COMPOUNDS PROVIDED BY EACH PARTY PURSUANT TO THE RESEARCH PROGRAM ARE
PROVIDED BY EACH PARTY "AS IS" AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL
WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE
WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-
INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES OR ARISING
FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT
THERETO.  Without limiting the generality of the foregoing, each Party expressly
does not warrant (i) that any compound it provides hereunder is free from any
third party rights or (ii) the safety or usefulness for any purpose of any
compound it provides hereunder.

     7.4  Terrapin Grant of Rights.  Terrapin has not, and will not during the
term of this Agreement, grant any right to any third party which would conflict
with the rights granted to Sanwa hereunder.  It has (or will have at the time
performance is due) maintained and will maintain and keep in full force and
effect all agreements necessary to perform its obligations hereunder.

                                   Article 8

                         Confidentiality; Publication

     8.1  Confidentiality.  Except to the extent expressly authorized by this
Agreement or otherwise agreed in writing by the Parties, the Parties agree that,
for the term of this Agreement and for [ * ] after its expiration or
termination, the receiving Party shall keep confidential and shall not publish
or otherwise disclose and shall not use for any purpose other than as provided
for in this Agreement any Confidential Information furnished to it by the other
Party pursuant to this Agreement or the Letter of Intent unless the receiving
Party can demonstrate by competent written proof that such Confidential
Information:

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       14
<PAGE>

          (a)  was already known to the receiving Party, other than under an
obligation of confidentiality, at the time of disclosure by the other Party;

          (b)  was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the receiving Party;

          (c)  became generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act or omission of
the receiving Party in breach of such Agreements;

          (d)  was disclosed to the receiving Party, other than under an
obligation of confidentiality to a third party, by a third party who had no
obligation to the disclosing Party not to disclose such information to others;
or

          (e)  was independently discovered or developed by the receiving Party
without the use of Confidential Information belonging to the disclosing Party.

     8.2  Authorized Disclosure.  Each Party may disclose Confidential
Information belonging to the other Party to the extent such disclosure is
reasonably necessary in the following instances:

          (a)  filing or prosecuting patents relating to Clinical Candidates or
Licensed Products;

          (b)  regulatory filings;

          (c)  prosecuting or defending litigation;

          (d)  complying with applicable governmental regulations;

          (e)  conducting preclinical or clinical trials of Clinical Candidates;

          (f)  disclosure to Affiliates, sublicensees, employees, consultants,
or agents each of whom prior to disclosure must be bound by similar obligations
of confidentiality and non-use at least equivalent in scope to those set forth
in this Article 8; and,

          (g)  disclosure to investment bankers; provided, however, that no such
disclosure shall be made of Sanwa Confidential Information without its written
consent, which consent shall not be unreasonably withheld.

Notwithstanding the foregoing, in the event a Party is required to make a
disclosure of the other Party's Confidential Information pursuant to this
Section 8.2 it will, except where impracticable, give reasonable advance notice
to the other Party of such disclosure and use best efforts to secure
confidential treatment of such information.  In any event, the

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       15
<PAGE>

Parties agree to take all reasonable action to avoid disclosure of Confidential
Information hereunder.

                                   Article 9

                             Term and Termination

     9.1  Term Of The Agreement. This Agreement shall become effective upon the
Effective Date. Unless earlier terminated pursuant to Sections 9.2, 9.3 or 9.4,
this Agreement shall continue in effect until the expiration or termination of
the License Agreement or, if no License Agreement has been entered into by the
one year anniversary of the end of the Research Term this Agreement shall
terminate on the one year anniversary of the end of the Research Term. The term
of this Agreement may be extended by mutual written agreement of the Parties.

     9.2  Termination For Material Breach.  Each Party shall have the right to
terminate this Agreement after [ * ] prior written notice to the other that the
other Party has committed a material breach of the Agreement, unless the other
Party cures (to the extent practicable) the material breach within such period
of time.  In the event of such termination by Sanwa due to Terrapin's material
breach, Sanwa may, for a period of [ * ] after such written notice of
termination, provide a Notice of Development and Commercialization with respect
to one or more Clinical Candidates.  Terrapin and Sanwa shall thereafter enter
into a License Agreement for any such Clinical Candidates or add any such
Clinical Candidate to any existing License Agreement as provided under Section
3.1 above; provided, however, that Sanwa shall, at its own expense, develop such
Clinical Candidates as set forth under Section 3.1.

     9.3  Termination Upon Bankruptcy.  Each Party shall have the right to
terminate this Agreement if the other Party (the "Bankrupt Party") becomes
insolvent or a petition in bankruptcy or for corporate reorganization or for any
similar relief is filed by or against such other Party or a receiver is
appointed with respect to any of the assets of such other Party or a liquidation
proceeding is commenced by or against such other Party.

     9.4  Accrued Rights; Surviving Obligations.  Termination of this Agreement
shall not affect any accrued rights of either Party.  The terms of Articles 3
(other than Section 3.4), 6, 8 and 10 of this Agreement shall survive
termination of this Agreement.  Except as set forth in the License Agreement,
promptly after termination of this Agreement each Party shall return or dispose
of any know-how of the other in accordance with the instructions of the other,
including without limitation any compounds, assays or other biological or
chemical materials.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       16
<PAGE>

                                  Article 10

                                   Indemnity

     10.1  Indemnification.  Each Party hereby agrees to save, defend and hold
the other Party and its directors, officers, employees, and agents harmless from
and against any and all claims, suits, actions, demands, liabilities, expenses
and/or loss, including reasonable legal expense and attorneys' fees
(collectively, "Claims") for damage to persons or property resulting directly or
indirectly from actions in connection with the Research Program by the
indemnifying Party, its Affiliates, agents or sublicensees, but only to the
extent such Claims result from the gross negligence or willful misconduct of the
indemnifying Party or its Affiliates, agents or sublicensees and do not result
from the negligence of the Party seeking indemnification.

     10.2  Control Of Defense.  Any entity entitled to indemnification under
this Article shall give notice to the indemnifying Party of any Claims that may
be subject to indemnification, promptly after learning of such Claim, and the
indemnifying Party shall assume the defense of such Claims with counsel
reasonably satisfactory to the indemnified Party.  If such defense is assumed by
the indemnifying Party with counsel so selected, the indemnifying Party will not
be subject to any liability for any settlement of such Claims made by the
indemnified Party without its consent (but such consent will not be unreasonably
withheld or delayed), and will not be obligated to pay the fees and expenses of
any separate counsel retained by the indemnified Party with respect to such
Claims.

                                  Article 11

                       Governing Law; Dispute Resolution

     11.1  Governing Law.  This Agreement shall be governed by and construed in
accordance with the domestic laws of the State of California, (i) without giving
effect to any choice or conflict of law provision or rule that would cause the
application of the laws of any jurisdiction other than the State of California,
and (ii) except that the rights of the parties to resolve by arbitration any
dispute arising between them regarding the subject matter of this Agreement
shall not be governed by the California arbitration act or international
arbitration act (Cal. Code of Civ. Proc. (S) 1280 et seq. and 1297.11 et seq.)
but rather by the United States Arbitration Act (9 U.S.C. (S)(S) 1-14, 201-208).

     11.2  Dispute Resolution.  In the event of any controversy or claim arising
out of, relating to or in connection with any provision of this Agreement, the
Parties shall try to settle their differences amicably and in good faith between
themselves first, by referring the disputed matter to the respective heads of
research of each Party and, if not resolved by the research heads, by referring
the disputed matter to the respective Chief

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       17
<PAGE>

Executive Officers of each Party.  In the event such executives are unable to
resolve such dispute within such thirty (30) day period, either Party may invoke
the provisions of Section 11.3.

     11.3  Arbitration.  Upon failure to resolve any controversy or claim
arising out of, relating to or in connection with any provision of this
Agreement using the dispute resolution procedure described in Section 11.2, such
controversy or claim shall be finally settled by arbitration.  Arbitration shall
be held in Honolulu, Hawaii in the English language and conducted in accordance
with the Commercial Arbitration Rules of the American Arbitration Association.
The decision of such arbitration shall be conclusive and binding upon both
Parties.  If a Party commences any action or proceeding against the other Party
to enforce this Agreement or any rights related thereto, the prevailing Party in
such action shall be entitled to recover from the other Party the reasonable
attorneys' fees and other reasonable costs and expenses incurred by that
prevailing Party in connection with such action or proceeding and in connection
with enforcing any judgment, award or order thereby obtained.

                                  Article 12

                              General Provisions

     12.1  Notices.  All notices required or permitted to be given under this
Agreement shall be in writing and shall be mailed by registered or certified
mail, postage prepaid, addressed to the signatory to whom such notice is
required or permitted to be given and transmitted by facsimile to the number
indicated below.  All notices shall be deemed to have been given when mailed, as
evidenced by the postmark at the point of mailing, or transmitted by facsimile.

     All notices to Sanwa shall be addressed as follows:

     Sanwa Kagaku Kenkyusho Co., Ltd.
     35 Higashi Sotobori-cho
     Higashi-ku Nagoya, 461
     Japan
     Attention:  President
     Fax:  011-81-52-9571067

     With a copy to:

     Graham & James, L.L.P.
     One Maritime Plaza, Suite 300
     San Francisco, California 94111
`
[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       18
<PAGE>

     U.S.A.
     Attention:  Michael R. Moyle, Esq.
     Fax:  (415) 391-2493

     All notices to Terrapin shall be addressed as follows:

     Terrapin Technologies, Inc.
     750 Gateway Boulevard
     South San Francisco, California 94080
     U.S.A.
     Attention:  President
     Fax: (415) 244-9388

     with a copy to:

     Cooley Godward LLP
     Five Palo Alto Square
     3000 El Camino Real
     Palo Alto, California  94306
     Attention:  Brian C. Cunningham, Esq.
     Fax:  (415) 857 0663

     Any Party may, by written notice to the other, designate a new addressee,
address or facsimile number to which notices to the Party giving the notice
shall thereafter be mailed or faxed.

     12.2  Force Majeure.  No Party shall be liable for any delay or failure of
performance to the extent such delay or failure is caused by circumstances
beyond its reasonable control and that by the exercise of due diligence it is
unable to prevent, provided that the Party claiming excuse uses its best efforts
to overcome the same.

     12.3  Entirety Of Agreement.  This Agreement embodies the entire, final and
complete agreement and understanding between the Parties and replaces and
supersedes all prior discussions and agreements between them with respect to its
subject matter, including the Letter of Intent, except as expressly stated
herein.  No modification or waiver of any terms or conditions hereof shall be
effective unless made in writing and signed by a duly authorized officer of each
Party.

     12.4  Non-Waiver.  The failure of a Party in any one or more instances to
insist upon strict performance of any of the terms and conditions of this
Agreement shall not constitute a waiver or relinquishment, to any extent, of the
right to assert or rely upon any such terms or conditions on any future
occasion.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       19
<PAGE>

     12.5  Disclaimer Of Agency.  Neither Party is, or will be deemed to be, the
legal representative or agent of the other, nor shall either Party have the
right or authority to assume, create, or incur any third party liability or
obligation of any kind, express or implied, against or in the name of or on
behalf of another except as expressly set forth in this Agreement.

     12.6  Severability.  If a court of competent jurisdiction declares any
provision of this Agreement invalid or unenforceable, or if any government or
other agency having jurisdiction over either Terrapin or Sanwa deems any
provision to be contrary to any laws, then that provision shall be severed and
the remainder of the Agreement shall continue in full force and effect.  To the
extent possible, the Parties shall revise such invalidated provision in a manner
that will render such provision valid without impairing the Parties' original
interest.

     12.7  Affiliates; Assignment.  Except as otherwise provided in this Section
12.7, neither Party may assign its rights or obligations under this Agreement
without the prior written consent of the other Party, except that a Party may
assign its rights or obligations to a third party in connection with the merger,
consolidation, reorganization or acquisition of stock or assets affecting
substantially all of the assets or actual voting control of the assigning Party.
This Agreement shall be binding upon the successors and permitted assigns of the
Parties. Any attempted delegation or assignment not in accordance with this
Section 12.7 shall be of no force or effect.

     12.8  Headings.  The headings contained in this Agreement have been added
for convenience only and shall not be construed as limiting.

     12.9  Limitation Of Liability.  No Party shall be liable to another for
indirect, incidental, consequential or special damages, including but not
limited to lost profits, arising from or relating to any breach of this
Agreement, regardless of any notice of the possibility of such damages.  Nothing
in this Section is intended to limit or restrict the indemnification rights or
obligations of any Party.

     12.10  Counterparts.  This Agreement may be executed in one or more
counterparts, each of which shall be an original and all of which shall
constitute together the same document.

     12.11  English Language.  This Agreement has been prepared in the English
language and shall be construed in the English language.

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       20
<PAGE>

     IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement.

TERRAPIN TECHNOLOGIES, INC.                 SANWA KAGAKU
                                            KENKYUSHO CO., LTD.

By:  /s/ Clifford Orent                     By:  /s/ Keiji Tanimoto
   -----------------------------               ---------------------------------

Name:   Clifford Orent                      Name:  Keiji Tanimoto

Title:  Chairman, President and Chief       Title: President and Chief Executive
        Executive Officer                          Officer

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       21
<PAGE>

                                   EXHIBIT A

                                      TO

                           COLLABORATION AGREEMENT

                                 RESEARCH PLAN

                                      [*]

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as  amended.

                                       22
<PAGE>

                                   EXHIBIT B

                                      TO

                           COLLABORATION AGREEMENT

                   DEVELOPMENT AND COMMERCIALIZATION NOTICE

This Development and Commercialization Notice is provided by Sanwa Kagaku
Kenkyusho Co., Ltd. ("Sanwa") to Terrapin Technologies, Inc. ("Terrapin"),
pursuant to Article 3 of the Collaboration Agreement between Sanwa and Terrapin,
dated as of December 20, 1996 (the "Collaboration Agreement").  All capitalized
terms contained in this notice but not defined herein will have the meaning set
forth in the Collaboration Agreement.

Sanwa hereby notifies Terrapin of its intention to develop the following
Clinical Candidate for use in the Field and, if results of the human clinical
studies justify, to prepare and file the Japanese equivalent of an NDA on such
Clinical Candidate for use in the Field:

                ______________________________________________
                     [Chemical Name of Clinical Candidate]

Such Clinical Candidate shall be included on Exhibit 1 to the License Agreement.

Sanwa Kagaku Kenkyusho Co., Ltd.

By:_______________________________

Printed Name:_____________________

Title:____________________________

Date:_____________________________

The undersigned has received the foregoing notice:

Terrapin Technologies, Inc.

By:_______________________________

Printed Name:_____________________

Title:____________________________

Date:_____________________________

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as  amended.

                                       23
<PAGE>

                                   Exhibit C

                               LICENSE AGREEMENT

The License Agreement has been filed with the SEC by Telik, Inc. as Exhibit 10.7
to this Telik Registration Statement Form S-1, filed March 31, 2000, which is
titled "License Agreement by and between Registrant and Sanwa Kagaku Kenkyusho
Co., Ltd., dated September 24, 1997, as amended," and is hereby incorporated by
reference.

[*]=CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
<PAGE>

                  FIRST AMENDMENT TO COLLABORATION AGREEMENT

     This First Amendment to Collaboration Agreement (this "First Amendment") is
made and dated September 24, 1997 (the "First Amendment Effective Date"), by and
between Sanwa Kagaku Kenkyusho Co., Ltd., a Japanese corporation ("Sanwa") and
Terrapin Technologies, inc., a Delaware corporation ("Terrapin").

                                   RECITALS

     A.   The Parties are parties to that Collaboration Agreement dated as of
December 20, 1996 (the "Collaboration Agreement') pursuant to which the parties
have jointly engaged in research to identify one or more compounds which
activate the insulin signal transduction pathway and appear to be useful for
treatment of diabetes mellitus or insulin resistance in humans.

     B.   The Parties are entering into a Series 1 Stock Purchase Agreement of
even date herewith (the `Stock Purchase Agreement") in connection with which, as
one of the conditions to Sanwa consummating the transactions contemplated by the
Stock Purchase Agreement, the parties have agreed to execute and deliver this
First Amendment, the License Agreement attached hereto as Exhibit A and a First
Amendment to Screening Services Agreement.

     NOW, THEREFORE, in consideration of the above recitals and for other good
and valuable consideration, the adequacy and receipt of which are hereby
acknowledged, the parties hereby agree as follows:

                                   AGREEMENT

     1.    Amendments.  The Collaboration Agreement is hereby amended as
follows:
          (a)  In Section 2.7 to the Collaboration Agreement, delete the
following phrase: "for which Sanwa has sent or plans to send a Development and
Commercialization Notice to Terrapin and"

          (b)  Revise Section 2.8.2 to the Collaboration Agreement to provide in
 its entirety as follows:

          2.8.2   The Parties shall make available and disclose to one another,
          on a quarterly basis through the RMC, all results of the work
          conducted pursuant to Phase 1 and Phase 2 of the Research Program.

          Further, upon the reasonable request of Sanwa and notice to Terrapin,
          Terrapin shall disclose to Sanwa all results of Terrapin's work
          conducted

[ * ] - Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       1
<PAGE>

          pursuant to the Research Program since the last date Terrapin
          disclosed such results to Sanwa.

          (c)  Add a new Section 2.10 to provide in its entirety as follows:

          2.10   Research Budget.  Within fifteen (15) business days after the
          First Amendment Effective Date, the parties shall agree and finalize a
          detailed budget ("Budget"), which shall be incorporated by reference
          herein in its entirety, and attached to this Agreement as Exhibit E.
          To the best of its present knowledge, Terrapin represents and warrants
          that [ * ].  Terrapin shall ensure at all times that it [ * ] and
          shall not [ * ] without the prior written consent of Sanwa, which
          consent shall not be unreasonably withheld.

          (d)  Article 3 shall be revised to read "License Agreement," and
Article 3 shall be revised in its entirety to read as follows:

          Article 3.  License Agreement.  As of the First Amendment Effective
          Date, the Parties are entering into a License Agreement, in the form
          attached hereto as Exhibit A, pursuant to which Terrapin is granting
          to Sanwa an exclusive license to all technology developed to date and
          technology to be developed under this Collaboration Agreement, such
          license to be in the Field and in the Sanwa Territory (as defined in
          such License Agreement to include Japan, Korea, Taiwan and the
          People's Republic of China).  At any time during the term of this
          Agreement, Sanwa shall provide written notice (the "Development and
          Commercialization Notice") to Terrapin of its intention to develop a
          Licensed Product for use in the Field and, if results of the human
          clinical studies justify, to prepare and file the Japanese equivalent
          of NDA on such Licensed Product for use in the Field.  Such notice
          shall be in the form attached hereto as Exhibit B and shall be made
          prior to the filing of the Japanese equivalent of an IND by Sanwa for
          such Licensed Product.  For each Licensed Product which Sanwa elects
          to develop and commercialize as set forth in this Article 3, Sanwa
          shall provide a new Development and Commercialization Notice to
          Terrapin.

          (e)  Delete Sections 3,1, 3.2, 3.3 and 3.4 in their entirety.

          (f)  Delete Section 5.2.2 in its entirety.

          (g)  Revise Section 6.3.2 to provide in its entirety as follows:

          6.3.2   Under the License Agreement.  Sanwa shall, at its own expense,
          assume responsibility for filing and prosecuting in the Sanwa
          Territory

[ * ] - Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       2
<PAGE>

          patent applications for, and maintaining patents on, Licensed
          Products. Upon the request of Sanwa, Terrapin shall transmit to Sanwa
          all information reasonable and appropriate in its possession relating
          to such patent application or patent and execute all consents or other
          filings reasonably necessary to permit Sanwa to assume such
          responsibility.

          (h)  Delete the last two sentences of Section 9.2.

          (i)  Revise Section 12.7 to provide in its entirety as follows:

          12.7  Assignment.

          12.7.1   General.  Except as otherwise provided in Section 12.7.2 or
          12.7.3, neither party may assign its rights or obligations under this
          Agreement without the prior written consent of the other party.  This
          Agreement shall be binding upon the permitted successors and permitted
          assigns of the Parties.  Any attempted delegation or assignment not in
          accordance with this Section 12.7 shall be of no force and effect.

          12.7.2   Permitted Assignment by Sanwa.  Sanwa may assign its rights
          or obligations under this Agreement to a third party in connection
          with the merger, consolidation, reorganization or acquisition of stock
          or assets affecting substantially all of the assets or actual voting
          control of Sanwa.

          12.7.3  Permitted Assignment by Terrapin.  Upon the written consent of
          Sanwa, such consent not to be unreasonably withheld or delayed,
          Terrapin may assign its rights or obligations under this Agreement to
          a third party in connection with the merger, consolidation,
          reorganization or acquisition of stock or assets affecting
          substantially all of the assets or actual voting control of Terrapin.
          Sanwa may only withhold its consent under the preceding sentence if
          (a) such third party [ * ] according to the terms of this Agreement or
          (b) such third party [ * ].

     2.   Defined Terms:  Incorporation.  Unless otherwise expressly provided
herein, defined terms used in this First Amendment shall have the same meaning
as set forth in the Collaboration Agreement, and all terms herein shall be
incorporated into the Collaboration Agreement. From and after the First
Amendment Effective Date, all reference to the "Collaboration Agreement" in all
other documents delivered in connection with the Collaboration Agreement shall
refer to the Collaboration Agreement, as amended hereby.

     3.   Counterparts:  Facsimile.  This First Amendment may be executed in
counterparts and by facsimile.

[ * ] - Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       3
<PAGE>

     IN WITNESS WHEREOF, the Parties have executed this First Amendment
effective as of the date first set forth above.

TERRAPIN TECHNOLOGIES, INC.            SANWA KAGAKU KENKYUSHO, CO. LTD.

/s/ Clifford Orent                     /s/ Keiji Tanimoto
------------------                     ------------------------------
By:                                    By:  Keiji Tanimoto

Its:                                   Its: President and CEO

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as  amended.
                                       4
<PAGE>

                  SECOND AMENDMENT TO COLLABORATION AGREEMENT

     This Second Amendment to Collaboration Agreement (this "Second Amendment")
is made and dated October 29, 1998 (the "Second Amendment Effective Date"), by
and between Sanwa Kagaku Kenkyusho Co., Ltd., a Japanese corporation ("Sanwa")
and Telik, Inc. (formerly Terrapin Technologies, Inc.), a Delaware corporation
("Telik").

                                   RECITALS

     A.   Sanwa and Telik are parties to that Collaboration Agreement dated as
of December 20, 1996, as amended by that certain First Amendment to
Collaboration Agreement dated September 24, 1997 (the "Collaboration Agreement")
pursuant to which the Parties have jointly engaged in research to identify one
or more compounds which activate the insulin signal transduction pathway and
appear to be useful for treatment of diabetes mellitus or insulin resistance in
humans.

     B.   Sanwa and Telik are entering into a Series J Preferred Stock Purchase
Agreement of even date herewith (the "Stock Purchase Agreement") in connection
with which, as one of the conditions to Sanwa consummating the transactions
contemplated by the Stock Purchase Agreement, the parties have agreed to execute
and deliver this Second Amendment.

     NOW, THEREFORE, in consideration of the above recitals and for other good
and valuable consideration, the adequacy and receipt of which are hereby
acknowledged, the parties hereby agree as follows:

                                   AGREEMENT

     4.   Amendments.  The Collaboration Agreement is hereby amended as follows:

          (a)  Each reference in the Collaboration Agreement to "Terrapin
Technologies, Inc." is amended and replaced by "Telik, Inc." Each reference in
the Collaboration Agreement to "Terrapin" is amended and replaced by "Telik."

          (b)  Section 2.1 is amended in its entirety as follows:

               The Parties will participate in a collaborative program (the
               "Research Program") to research and discover novel compounds for
               use in the Field.  The Research Program shall commence on the
               Effective Date and continue until the [ * ], unless (i) earlier
               terminated pursuant to Sections 9.2 and 9.3, (ii) extended
               pursuant to Section 2.10, or (iii) extended by mutual written
               agreement of the Parties.  The period of time during which the
               Research Program is in effect shall be the "Research Term."  The
               Research Program shall be

[ * ] - Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       1
<PAGE>

               conducted pursuant to a detailed research plan attached hereto as
               Exhibit A, which may be modified from time to time by the RMC
               (the "Research Plan"). Telik shall commence the Research Program
               promptly upon execution of this Agreement. Each Party shall
               devote commercially reasonable efforts to its obligations under
               the Research Program, consistent with the efforts it devotes to
               its own research programs of comparable market potential.

          (c)  Section 2.5.1 is amended in its entirety as follows:

               Telik will be responsible for providing [ * ] (the [ * ] all
               infrastructure [ * ] necessary for conducting [ * ] Phase 1 of
               the Research Plan, relating to identification and selection of
               advanced lead compounds and Phase 2 of the Research Plan,
               relating to identification and selection of Clinical Candidates.
               Telik, [ * ] will also be responsible for providing all
               infrastructure [ * ] necessary for and conducting [ * ], Phase 3
               of the Research Plan, relating to all IND enabling work for
               Clinical Candidates, except that portion of Phase 3 work
               identified in the Research Plan as uniquely required for an IND
               application in Japan, for:

               (i)  The first Clinical Candidate; and

               (ii) Subsequent Clinical Candidates if Telik shall choose by
written notice to Sanwa, to develop or have developed the same Clinical
Candidate(s) outside the Sanwa Territory.

               If, as of the date Telik provides notice to Sanwa pursuant to
               Section 2.5.l(ii), Sanwa has commenced work on that portion of
               Phase 3 of the Research Plan for which Telik would be responsible
               as a result of providing such notice using protocols for such
               Phase 3 work as may be recommended by the RMC, then Telik shall
               promptly [ * ] such portion of Phase 3 of the Research Plan and
               Telik shall take over and complete or have such work completed.

          (d)  Section 2.10 is amended by renumbering the existing Section 2.10
as Section 2.10 "(a)" and by adding the following at the end of that section:

               (b)  At each of the RMC meetings, the RMC will discuss whether it
               would be scientifically advisable to extend the Research Term for
               an additional [ * ] period.  By no later than [ * ] ("Cut-Off
               Date"), the RMC shall make a final recommendation to the Parties
               of whether to extend the Research Term for an additional [ * ]
               period.

[ * ] - Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       2
<PAGE>

               If at any RMC meeting the RMC recommends to extend the Research
               Term for an additional [ * ] period, the Research Term shall be
               extended until the [ * ]. If by the Cut-Off Date the RMC has not
               made a final recommendation to extend the Research Term for an
               additional [ * ] period or if the RMC has recommended not to
               extend the Research Term for an additional [ * ] period, Sanwa
               may, at its option exercisable no later than [ * ] after the Cut-
               Off Date upon written notice to Telik, extend the Research Term
               for an additional [ * ]. Upon Sanwa's exercise of its option to
               extend the Research Term, the Research Term shall be extended
               until the [ * ].

               (c) Sanwa agrees that if the Research Term is extended for an
               additional [ * ] period pursuant to Section 2.10 (b), then Sanwa
               will make an additional research payment to Telik of [ * ] within
               [ * ] after the [ * ], subject to the conditions set forth in the
               last two sentences in Section 5.3.

               (d) Telik shall be fully responsible for performing all work [ *
               ] (the [ * ] during any extensions to the Research Term and
               ensuring that at all times Telik [ * ] during any such extensions
               to the Research Term.

          (e)  Section 5.4 is amended by adding the following clause to the
end of that section:

               Furthermore, the amount of each of the foregoing payments shall
               be [ * ] at the time the Milestone Events occur as follows:

               (i)    [ * ]

               (ii)   [ * ]; and

               (iii)  [ * ].

     5.   Defined Terms; Incorporation.  Unless otherwise expressly provided
herein, defined terms used in this Second Amendment shall have the same meaning
as set forth in the Collaboration Agreement, and all terms herein shall be
incorporated into the Collaboration Agreement. From and after the Second
Amendment Effective Date, all references to the "Collaboration Agreement" in all
other documents delivered in connection with the Collaboration Agreement shall
refer to the Collaboration Agreement, as amended hereby.

     6.   Counterparts; Facsimile.  This Second Amendment may be executed in
counterparts and by facsimile.

[ * ] - Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

                                       3
<PAGE>

     IN WITNESS WHEREOF, the Parties have executed this Second Amendment
effective as of the date first set forth above.

TELIK, INC.                            SANWA KAGAKU KENKYUSHO, CO. LTD.

/s/ Clifford Orent                     /s/ Keiji Tanimoto
-----------------------------          -----------------------------------
By:  Clifford Orent                    By:  Keiji Tanimoto
Its: Chairman and Chief                Its: President and Chief Executive
     Executive Officer                      Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}]]